Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 12543-3209; 70121-1218
UNII 80168379AG
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Embolism24.01.01.0090.000280%
Haematotoxicity12.03.01.025; 01.05.01.0070.000839%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.000336%Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.000448%Not Available
Malnutrition14.03.02.0040.000392%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.007--Not Available
Neoplasm progression16.16.02.0050.003940%Not Available
Oral neoplasm16.13.09.002; 07.21.08.002--Not Available
Perineal pain21.10.01.0030.000112%
Peripheral embolism24.01.02.0050.000112%Not Available
Cardiac valve disease02.07.02.0010.000112%Not Available
Venous thrombosis limb24.01.02.0090.000280%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.002071%
Ill-defined disorder08.01.03.049--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Red blood cell abnormality01.07.02.006--Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.0090.002350%Not Available
Disease progression08.01.03.0380.007063%
Disease recurrence08.01.03.0500.000974%Not Available
Neoplasm recurrence16.16.02.0040.000302%Not Available
Pulmonary toxicity12.03.01.013; 22.01.02.0070.000336%Not Available
Hepatobiliary disease09.01.08.0030.000112%Not Available
Hyperlipidaemia14.08.03.001--
Large intestinal obstruction07.13.03.0030.000224%
Pigmentation disorder23.05.03.0010.000112%Not Available
Metastasis16.22.01.0010.000112%Not Available
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene